Preisler H D, Bjornsson S, Mori M, Lyman G H
Br J Cancer. 1976 Jun;33(6):634-45. doi: 10.1038/bjc.1976.101.
Studies were conducted of the in vivo therapeutic potential of compounds which induce the differentiation of Friend leukaemia cells (FLC) in vitro. DBA2/J mice were inoculated with Friend leukaemia cells grown in tissue culture and at various times thereafter were treated with either N-methylacetamide, dimethylacetamide, or tetramethylurea. While survival was only occasionally prolonged, in every study these agents significantly inhibited leukaemia cell proliferation in the spleen and to a lesser extent in the marrow. These agents had no effect on the rate of proliferation of FLC growing subcutaneously nor on the proliferation of myeloid leukaemia in RFMS mice. These studies indicate that the administration of inducing agents to mice bearing Friend leukaemia can alter the proliferation characteristics of the leukaemia cells and hence suggest that these agents may have therapeutic potential.
对在体外诱导弗氏白血病细胞(FLC)分化的化合物的体内治疗潜力进行了研究。将在组织培养中生长的弗氏白血病细胞接种到DBA2/J小鼠体内,此后在不同时间用N-甲基乙酰胺、二甲基乙酰胺或四甲基脲进行治疗。虽然存活时间仅偶尔延长,但在每项研究中,这些药物均显著抑制脾脏中的白血病细胞增殖,对骨髓中的抑制作用较小。这些药物对皮下生长的FLC的增殖速率或RFMS小鼠的髓系白血病增殖均无影响。这些研究表明,给患有弗氏白血病的小鼠施用诱导剂可改变白血病细胞的增殖特性,因此表明这些药物可能具有治疗潜力。